Trial · NCT02817347
A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
NCT02817347, Phase 1, Phase 2, Terminated, Yuhan Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea. Trials, record NCT02817347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02817347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
- NCT number
- NCT02817347
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 135 participants, actual
- Lead sponsor
- Yuhan Corporation
- Conditions
- Otitis Media, Otorrhea
- Interventions
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%, piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%, piperacillin 2% + tazobactam 0.25%, piperacillin 4% + tazobactam 0.5%, piperacillin 8% + tazobactam 1.0%
- First posted
- 2016-06-29
- Last updated
- 2022-01-13
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients achieving cessation of otorrhea on Day 15. | Day 15 | The proportion of patients achieving cessation of otorrhea (grade 0) on Day 15, as evidenced by otoscopy |
| Secondary | The proportion of patients with cessation of otorrhea on Day 8. | Day 8 | The proportion of patients with cessation of otorrhea on Day 8 as evidenced by otoscopy. |
| Secondary | The proportion of patients with cessation of otorrhea on Day 22. | Day 22 | The proportion of patients with cessation of otorrhea on Day 22 as evidenced by otoscopy. |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 8 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 15 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 22 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Microbiological eradication | Day 8, 15, 22 | Proportion of patients with microbiological eradicationat each visit |
| Other | Cmax | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Maximum plasma concentration |
| Other | AUClast | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | The area under the plasma concentration-time curve from time zero until the last measurable concentration |
| Other | AUCinf | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | The area under the plasma concentration - time curve from time zero to infinite time |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02817347
GET https://conductscience.org/api/trials/v1/NCT02817347/registered